Herpes labialis

Oramed Letter to Shareholders

Retrieved on: 
Tuesday, February 20, 2024
Acquisition, Senior, Letter, Joint venture, Investment, Marketing, FDA, Hemorrhoid, Note, Herpes labialis, Wart, JV, BMI, License, Patient, Pruritus ani, Anal, Body mass index, Failure, Glycated hemoglobin, Partnership, Pharmaceutical industry

NEW YORK, Feb. 20, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its President and Chief Executive Officer, Nadav Kidron.

Key Points: 
  • NEW YORK, Feb. 20, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its President and Chief Executive Officer, Nadav Kidron.
  • I am pleased to share with you an update regarding Oramed.
  • Oramed and HTIT Joint Venture:
    In January 2024, Oramed entered into a definitive agreement with HTIT, marking a milestone in the creation of a joint venture ("JV"), centered around Oramed's cutting-edge oral drug delivery technology.
  • We thank you for your support and look forward to keeping our shareholders updated on the important milestones ahead.

DGAP-News: It All Comes Down To Science And Research With The Efficacy Of Jupiter Wellness’s Lineup Of Skin And Hair Treatment Drugs

Retrieved on: 
Tuesday, September 6, 2022
CBD, Pachydactylus labialis, Burns, Patient, Breast cancer, Burn, Advertising, Female, NYSE, OTC, Sexual desire, Research, Hair, NASDAQ, Amazon (company), Pfizer, PFE, Food and Drug Administration, Man, Vitiligo, Sale, Walmart, Food, Skin, Herpes labialis, Psoriasis, Pleasure, Simplex, Dermatitis, WMT, Social media, FDA, Mouth, Atopic dermatitis, Hair loss, Skin care, Intellectual property, Woman, Minoxidil, Health, Biology, AMZN, Cosmetics, Pharmaceutical industry, Petroleum jelly, Dietary supplement, Crisaborole

Jupiter Wellness Inc. (NASDAQ: JUPW), which focuses on making drugs and skin- and hair-care products, is riding on this emerging trend.

Key Points: 
  • Jupiter Wellness Inc. (NASDAQ: JUPW), which focuses on making drugs and skin- and hair-care products, is riding on this emerging trend.
  • Jupiters development pipeline includes products to address psoriasis, eczema, burns, herpes and cold sores, hair loss and female libido loss.
  • It reportedly works by enriching the sulfotransferase enzyme in the hair and amping up the efficacy of Minoxidil for hair loss.
  • I am pleased to report that Jupiter Wellness is on track with its 2022 roadmap, Jupiter Wellness CEO Brian John said.

QIAGEN Launches Syndromic Test for QIAstat-Dx Device to Combat Global Monkeypox Health Emergency

Retrieved on: 
Monday, August 15, 2022
Health, Infectious Diseases, Clinical Trials, Research, Pharmaceutical, Science, U.S. Securities and Exchange Commission, Â, Monkeypox, Union, Public health, Laboratory, World Health Organization, Budget, VZV, NYSE, Senior, HSV2, Growth, SEC, Research, Life, Government, Blood, European, DNA, COVID-19, Infection, Urinary tract infection, QIAGEN, List of life sciences, HH6, RNA, RUO, Gold standard (test), Herpes labialis, Enterovirus, Knowledge, WHO, World, Automation, QGEN, Meningitis, Protein, Monkeypox virus, Molecular diagnostics, PCR, Solution, LDT, HSV1, Vaccine, Pharmaceutical industry, Insight

The new panel currently for research use only (RUO) comes in cartridge form to run on QIAGENs QIAstat-Dx automated syndromic testing devices.

Key Points: 
  • The new panel currently for research use only (RUO) comes in cartridge form to run on QIAGENs QIAstat-Dx automated syndromic testing devices.
  • Currently the worlds only syndromic test for the pathogen, the panel will prove to be crucial for detecting and then combatting the spread of monkeypox around the globe.
  • The panels RUO-status means it currently can only be used for the surveillance not screening or diagnosing of monkeypox cases.
  • QIAGEN teams around the world are working with healthcare authorities to support testing for the monkeypox virus outbreak.

Virios Therapeutics: The 'Virus Hypothesis' That Stands to Change the Lives of 10M Americans

Retrieved on: 
Tuesday, August 9, 2022
FDA, U.S. Securities and Exchange Commission, Depression, Randomized controlled trial, Risk, Famciclovir, Trial of the century, Forward-looking statement, Simplex, Diagnosis, Clinical trial, LLC, Motivation, Security (finance), Research, PCG, Human, Pain, Enzyme, Annual report, Communication, Patient, Celecoxib, DNA, Therapy, Fatigue, Review, Central nervous system, Safety, FM, Virus, Anxiety, Private Securities Litigation Reform Act, Fibromyalgia, Nasdaq, Potyvirus, Functional gastrointestinal disorder, Herpes labialis, Disease, Pharmaceutical industry, Vaccine, Medical device

Dr. William Pridgen, the founder of Virios Therapeutics, Inc. has observed the effects of virus reactivation firsthand.

Key Points: 
  • Dr. William Pridgen, the founder of Virios Therapeutics, Inc. has observed the effects of virus reactivation firsthand.
  • Q: Can you tell us about FM and how IMC-1, Virios Therapeutics' lead product candidate, could potentially be an effective treatment?
  • Q: Based on your real-world experience, can you tell us more about how IMC-1 has the potential to change lives?
  • It is an exciting time for Virios and its shareholders but more than that, it has the potential to completely change the lives of FM patients.

Global Viral Transport Medium Market Report 2022-2027 Featuring Key Vendors - BD, Hardy DX, HiMedia Labs, Laboratory Corp of America, Puritan Medical Products, Thermo Fisher Scientific, & Vircell - ResearchAndMarkets.com

Retrieved on: 
Monday, August 8, 2022
Health, Infectious Diseases, FDA, Antibody, Herpes labialis, Mortality, Simplex, Diagnosis, Population, Growth, Chickenpox, RSV, SARS-COV-2, Hardy Diagnostics, Hospital, Prevalence, Research, Respiratory syncytial virus, Patient, Viral disease, Degenerative disease, COVID-19, Infection, Vaccine, Ageing, Transport, Nature, Enterovirus, Disease, Maintenance, PLOS, Solution, VTM, Collection, Pharmacy, Thermo Fisher Scientific, Animal, Pharmaceutical industry

More recently, the sudden onset of the COVID-19 pandemic significantly changed the demand for transport medium products and related kits.

Key Points: 
  • More recently, the sudden onset of the COVID-19 pandemic significantly changed the demand for transport medium products and related kits.
  • Owing to the surge in demand for diagnostic tests and sample collection from people, many vendors increased their production.
  • Most of the leading and emerging companies took part in fulfilling VTM supply across the healthcare system in the world.
  • The global viral transport medium market is highly competitive in nature due to the presence of domestic, regional, and international market players.

Global Genital Herpes Treatment Market Outlook Report 2022-2027 Featuring Key Vendors - GlaxoSmithKline, Glenmark Pharmaceuticals, Viatris, Novartis, Teva Pharmaceuticals, & Bausch Health Companies - ResearchAndMarkets.com

Retrieved on: 
Friday, August 5, 2022
Infectious Diseases, Pharmaceutical, Health, People, FDA, LGBT, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Woman, Ageing, Valaciclovir, Pharmacy, Retail, Risk, MSM, Famciclovir, Recurrence, Sex organ, Food, Simplex, Population, NE, Geography, GSK, Incidence, IND, Man, HSV, Patient, HSV-2, Company, Genital herpes, Vaccine, STD, OTC, Infection, Awareness, Immunodeficiency, Sanofi, Herpes labialis, WHO, Technology, Herpes simplex virus, HIV, Factor X, Sex, STI, Vertically transmitted infection, Investigational New Drug, Pharmaceutical industry, Birth control, Aciclovir, Aciclovir, Pritelivir, Moderna

The "Genital Herpes Treatment Market - Global Outlook and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Genital Herpes Treatment Market - Global Outlook and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global genital herpes treatment market is segmented based on drug type, distribution channel, virus type, route of administration, and geography.
  • HSV-2 is the leading virus type segment as HSV-2 is the leading cause of genital herpes.
  • North America is the major revenue contributor to the global genital herpes treatment market, with a share of more than 40%.

Navamedic ASA - Exclusive agreement with Vectans Pharma for the unique cold sore treatment product Sitavig®

Retrieved on: 
Thursday, August 4, 2022
Sores, Pachydactylus labialis, CEO, Population, Lip, Sale, Herpes labialis, Mouth, Marketing, Patient, Aciclovir, Nordic, Acquisition, Partnership, OTC, Herpes simplex virus, Ownership, Pharmaceutical industry, Vaccine

This entitles Navamedic to the ownership of the marketing authorizations for the product in these regions.

Key Points: 
  • This entitles Navamedic to the ownership of the marketing authorizations for the product in these regions.
  • It is a key element of our value creation strategy to secure and increase value creation through ownership of products and exclusive marketing rights," says Kathrine Gamborg Andreassen, CEO of Navamedic ASA.
  • Cold sores - also called fever blisters - is a common and recurring condition that affects about 20 - 40% of the population.
  • Sitavig (acyclovir) is a 50mg Muco-Adhesive Buccal tablet that represents a breakthrough in the treatment of cold sores.

Eurocine Vaccines expands its portfolio with a therapeutic HSV-2 vaccine candidate

Retrieved on: 
Tuesday, June 14, 2022
Vaccine, Research, Depression, Ulcer, CEO, Immediate, WHO, RNA transfection, Risk, Technology, Encephalitis, EU, Herpes labialis, Simplex, Quality of life, Food industry, HIV, HSV-2, Documentation, Protein, Pharmaceutical industry, Pfizer

STOCKHOLM, June 14, 2022 /PRNewswire/ --Eurocine Vaccines AB ("Eurocine Vaccines") hereby announces that the company has entered into a research and collaboration agreement with Redbiotec AG ("Redbiotec").

Key Points: 
  • STOCKHOLM, June 14, 2022 /PRNewswire/ --Eurocine Vaccines AB ("Eurocine Vaccines") hereby announces that the company has entered into a research and collaboration agreement with Redbiotec AG ("Redbiotec").
  • Redbiotec has a right to royalties on Eurocine Vaccines net sales of an approved HSV-2 vaccine, should such sales arise.
  • "I am very pleased that we have added this promising candidate to our portfolio, especially given the impressive scientific development of the therapeutic vaccine made to this point by Redbiotec," says CEO Hans Arwidsson, Eurocine Vaccines.
  • Evaluate the potential of a prophylactic HSV-2 vaccine to follow the development of this therapeutic vaccine, and the potential synergies of these two.

Eurocine Vaccines expands its portfolio with a therapeutic HSV-2 vaccine candidate

Retrieved on: 
Tuesday, June 14, 2022
Vaccine, Research, Depression, Ulcer, CEO, Immediate, WHO, RNA transfection, Risk, Technology, Encephalitis, EU, Herpes labialis, Simplex, Quality of life, Food industry, HIV, HSV-2, Documentation, Protein, Pharmaceutical industry, Pfizer

STOCKHOLM, June 14, 2022 /PRNewswire/ --Eurocine Vaccines AB ("Eurocine Vaccines") hereby announces that the company has entered into a research and collaboration agreement with Redbiotec AG ("Redbiotec").

Key Points: 
  • STOCKHOLM, June 14, 2022 /PRNewswire/ --Eurocine Vaccines AB ("Eurocine Vaccines") hereby announces that the company has entered into a research and collaboration agreement with Redbiotec AG ("Redbiotec").
  • Redbiotec has a right to royalties on Eurocine Vaccines net sales of an approved HSV-2 vaccine, should such sales arise.
  • "I am very pleased that we have added this promising candidate to our portfolio, especially given the impressive scientific development of the therapeutic vaccine made to this point by Redbiotec," says CEO Hans Arwidsson, Eurocine Vaccines.
  • Evaluate the potential of a prophylactic HSV-2 vaccine to follow the development of this therapeutic vaccine, and the potential synergies of these two.

Sorrento Therapeutics Announces FDA Clearance of Its IND Application of Next Generation oHSV Oncolytic Virus STI-1386 for Patients With Relapsed and Refractory Solid Tumors

Retrieved on: 
Monday, December 20, 2021
Therapy, Antiviral drug, TGF, Doctor of Philosophy, SAN, STI, Acquisition, Risk, TRPV1, MBA, Interleukin, Trial of the century, Antibody, Senior, 1386, Forward-looking statement, NK, FDA, Oncolytic herpes virus, Pain, Safety, Cancer, Tumor microenvironment, U.S. Securities and Exchange Commission, Vaccine, Security (finance), MD, GLOBE, Sarcoma, JD, Relapse, Autoimmune disease, Cell, RTX, Sciatica, Herpes labialis, Osteoarthritis, Trigeminal neuralgia, Transgene, Food, Private Securities Litigation Reform Act, Annual report, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Neoplasm, Pharmaceutical industry, Generic drug, Patient, COVID-19

STI-1386, or Seprehvec, is a 2nd generation oncolytic herpes simplex virus type 1 (oHSV) developed following the acquisition of Virttu Biologics by Sorrento in 2017 and produced in Sorrentos GMP virus therapeutics manufacturing facility.

Key Points: 
  • STI-1386, or Seprehvec, is a 2nd generation oncolytic herpes simplex virus type 1 (oHSV) developed following the acquisition of Virttu Biologics by Sorrento in 2017 and produced in Sorrentos GMP virus therapeutics manufacturing facility.
  • Seprehvec additionally expresses transgenes encoding an anti-PD-1 scFv-Fc isolated from the Sorrento G-MAB antibody library, a TGF beta receptor 2 decoy, and interleukin-12.
  • Seprehvec allows for locoregional immune stimulation at the tumor site while potentially minimizing the undesired effects that may accompany systemic immune stimulation.
  • RTX has completed a Phase IB trial for intractable pain associated with cancer and a Phase 1B trial in osteoarthritis patients.